Based on the clinical features of myeloma and related malignancies of plasma cells, it has
been possible to generate a model system of myeloma progression from a normal plasma …

The ability to rearrange the germ-line DNA to generate antibody diversity is an essential
prerequisite for the production of a functional repertoire. While this is essential to prevent …

The introduction of bortezomib, a novel first-in-class proteasome inhibitor, has been a major
break through in the treatment of multiple myeloma. It is currently approved for the treatment …

Background High-dose therapy with supporting autologous stem-cell transplantation
remains a controversial treatment for cancer. In multiple myeloma, first-line regimens …

The antiangiogenic activity of thalidomide (Thal), coupled with an increase in bone marrow
angiogenesis in multiple myeloma (MM), provided the rationale for the use of Thal in MM …

Background Bisphosphonates reduce the risk of skeletal events in patients with malignant
bone disease, and zoledronic acid has shown potential anticancer effects in preclinical and …

Purpose At the molecular level, myeloma is characterized by copy number abnormalities
and recurrent translocations into the immunoglobulin heavy chain locus. Novel methods …

A novel nonmyeloablative conditioning regimen was investigated in 44 patients with
hematologic malignancies. The median patient age was 41 years. Many of the patients had …

Minimal Residual Disease Assessed by Multiparameter Flow Cytometry in Multiple Myeloma:
Impact on Outcome in the Medical Researc Page 1 Minimal Residual Disease Assessed by …

Thalidomide maintenance has the potential to modulate residual multiple myeloma (MM)
after an initial response. This trial compared the effect of thalidomide maintenance and no …